Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCDIN3D | Q7Z5W3 | 4/20 | 0.46 |
| ▸ | PDE5A | O76074 | 5/20 | 0.41 |
| ▸ | PDE11A | Q9HCR9 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7199261 | 0.92 | PDE11A (0.44) | BCDIN3DPDE5APDE11A | |
| Dimethylamine SCHEMBL2325793 | 0.90 | BCDIN3D (0.42) | BCDIN3DPDE5APDE11A | |
| SCHEMBL6706993 | 0.89 | PDE11A (0.44) | BCDIN3DPDE5APDE11A | |
| SCHEMBL6706955 | 0.89 | PDE11A (0.44) | BCDIN3DPDE5APDE11A | |
| SCHEMBL6753661 | 0.89 | PDE5A (0.43) | BCDIN3DPDE5APDE11A | |
| SCHEMBL6707009 | 0.88 | PDE11A (0.43) | BCDIN3DPDE5APDE11A | |
| SCHEMBL6706970 | 0.88 | PDE11A (0.43) | BCDIN3DPDE5APDE11A | |
| SCHEMBL6706949 | 0.88 | PDE11A (0.43) | BCDIN3DPDE5APDE11A | |
| SCHEMBL2324275 | 0.88 | BCDIN3D (0.42) | BCDIN3DPDE5APDE11A | |
| SCHEMBL2324827 | 0.87 | PDE5A (0.44) | BCDIN3DPDE5APDE11A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1296986-B1 | 5-AMINOALKYL-PYRAZOLO[ 4,3-D]PYRIMIDINES WITH A PHOSPHODIESTERASE V-INHIBITING EFFECT | MERCK PATENT GMBH (DE) | 2011-08-10 | — | — | EP | disclosed |
| US-7060823-B2 | 5-aminoalkyl-pyrazolo[4,3-d]pyrimidines with a phosphodiesterase v-inhibiting effect | MERCK PATENT GMBH (DE) | 2006-06-13 | — | — | US | disclosed |
| US-20040029900-A1 | 5-Aminoalkyl-pyrazolo[4,3-d]pyrimidines with a phosphodiesterase v-inhibiting effect | MERCK PATENT GMBH (DE) | 2004-02-12 | — | — | US | disclosed |
| EP-1296986-A1 | 5-AMINOALKYL-PYRAZOLO 4,3-D]PYRIMIDINES WITH A PHOSPHODIESTERASE V-INHIBITING EFFECT | MERCK PATENT GmbH (DE) | 2003-04-02 | — | — | EP | disclosed |
| WO-2002000660-A1 | 5-AMINOALKYL-PYRAZOLO[4,3-D]PYRIMIDINES WITH A PHOSPHODIESTERASE V-INHIBITING EFFECT | MERCK PATENT GMBH (DE) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029900-A1 | 5-Aminoalkyl-pyrazolo[4,3-d]pyrimidines with a phosphodiesterase v-inhibiting effect | PDE3A, PDE5A, PDE3B | BCDIN3D 544/4885PDE5A 2/4885PDE11A 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.